While LGP1 markedly alleviated the histopathological changes in the kidney and lowered FBG, FINS, and insulin sensitivity index (ISI) levels and caspase-3/8/9, Bax, and NF-κB protein expressions, LGP2 had no impact (Wen et al., 2013), suggesting that LGP1 could attenuate and treat the progression of DN through regulating several molecular targets. The gene discussed is GHDC; the disease is liver dysplastic nodule.